Navigation Links
When nerve meets muscle, biglycan seals the deal
Date:2/14/2012

PROVIDENCE, R.I. [Brown University] A protein that has shown early promise in preventing the loss of muscle function in mouse models of Duchenne muscular dystrophy, has been found in a new study to be a key player in the process of joining nerves to muscles.

The protein biglycan needs to be present to stabilize synapses at the neuromuscular junction after they have formed, according to research led by Brown University that appears in the Feb. 14, 2012, issue of the Journal of Neruoscience.

"What neuromuscular junctions do second-by-second is essential for our brain to control movement and they are also important for the long-term health of both muscle and motor neurons," said Justin Fallon, profesor of neuroscience at Brown University and the paper's senior author. "A treatment that sustains or supports the synapse could promote the health of motor neurons and muscle."

In previous work, Fallon, a member of the Brown Institute for Brain Science, has shown that in mice with the same genetic mutation as Duchenne patients, biglycan promotes the activity of another natural protein, utrophin, that can significantly reduce the muscle degradation that patients suffer. Utrophin essentially takes over for dystrophin, which is the protein Duchenne patients cannot produce. In 2010 Brown licensed Fallon's biglycan intellectual property to the Providence startup company Tivorsan Pharmaceuticals, which is working toward human trials of biglycan.

Last month the Muscular Dystrophy Association, which helped support Fallon's new study, gave Tivorsan a $1 million grant.

Now Fallon's research group has found another important role for biglycan. In the new multi-institutional study, lead author Alison Amenta and a team of other scientists found that biglycan binds and helps activate and target a receptor enzyme called MuSK, which works like a foreman or master regulator over other proteins that build and stabilize the neuromus
'/>"/>

Contact: David Orenstein
david_orenstein@brown.edu
401-863-1862
Brown University
Source:Eurekalert  

Page: 1 2

Related biology technology :

1. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
2. OSU chemist developing solution to nerve agent exposure
3. Weizmann Institute scientists used accelerated evolution to develop enzymes that provide protection against nerve gas
4. Weizmann Institute scientists used accelerated evolution to develop enzymes that provide protection against nerve gas
5. Biosynthetic corneas formulated with recombinant collagen restore vision and nerve growth
6. New insight in nerve cell communication
7. UCF teams advanced nerve cell system could help cure diabetic neuropathy, related diseases
8. Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients
9. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
10. AllograftPossibilities.org Meets Unmet Need for Consumer-Oriented Information on Tissue Donation, Transplantation on the Internet
11. President Obama Meets U.S. Laureates of 2010 Kavli Prizes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
When nerve meets muscle, biglycan seals the deal
(Date:3/4/2015)... March 4, 2015   ... für Diagnostik und Therapie, Strahlendosismanagement und IT-Lösungen für ... Royal Philips (NYSE: PHG, AEX: PHIA) ... 2015 (ECR) bekannt, der vom 4. bis 8. März ... den Ständen Nr. 102 and 110 ...
(Date:3/3/2015)... March 3, 2015 NASA astronaut Scott Kelly ... month to spend a year living and working on the ... from 5:30 to 7 a.m. EDT Monday, March 9. ... as he completes the final weeks of his training. The ... on NASA Television highlighting his mission training and previous spaceflights. ...
(Date:3/3/2015)... , Mar. 03, 2015 Research and Markets ... the "Gene Therapy Market, 2015 - 2025" ... Therapy Market, 2015-2025" report provides an extensive study on ... research has been carried out in this field for ... therapies (four available in Asian markets; one approved in ...
(Date:3/3/2015)... SEATTLE , March 3, 2015 Adaptive ... Group CFO, is joining its Board of Director as ... financial officer at Zillow Group, Chad oversees all finance, ... Chad built the company,s core finance, treasury and accounting ... IPO and nine acquisitions. In 2013, he was named ...
Breaking Biology Technology:Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2
... Wash., March 11 SCOLR Pharma, Inc. (NYSE Alternext ... and twelve months ended December 31, 2008. The ... 11, 2009, at 11:30 a.m. (Eastern Daylight Time)."Last year ... and CEO Bruce S. Morra, Ph.D., M.B.A. "Utilizing our ...
... Serve Future Requirements of Stem Cell ResearchersST. LOUIS, March ... announced the launch of an online web portal that ... of industry-leading products developed specifically for advanced stem cell ... highly-focused products that are expected to support every step ...
... March 11 Insmed Inc. (Nasdaq: INSM ), a developer of ... ended December 31, 2008. Company Highlights , ... Insmed entered into ... will purchase all assets related to Insmed,s follow-on biologics platform. , ...
Cached Biology Technology:SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 2SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 3SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 4SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 5SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 6SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 7SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 8Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal 2Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal 3Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 2Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 3Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 4Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 5Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 6Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 7Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 8Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 9Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 10
(Date:3/4/2015)... DUBLIN , Mar. 04, 2015 Research ... announced the addition of the "Global Biometrics ... their offering. The market for biometric ... CAGR of around 14% till 2020 ... will be increasing security needs, government projects and ...
(Date:3/3/2015)... FOREST, Calif. , March 3, 2015 ... the leading provider of advanced cryogenic logistics ... markets including immunotherapies, stem cells, cell lines, ... and reproductive medicine, today announced the expansion ... Cancer Research Centers, ("Fred Hutch") Clinical ...
(Date:3/2/2015)... 2, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new implementation of ... enable rapid and secure transactions and reliable identification ... is a turnkey solution providing mouse and keyboard ... integrate fingerprint ID solutions into their product offerings, ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
... the Johns Hopkins School of Medicine and their colleagues have ... addition to their own can acquire new color vision, a ... new sensory information than anticipated. , This work, appearing ... ancestral primate inherited a new type of photoreceptor more than ...
... aren't as busy as, well, a bee. It all ... that a key to the insects' success in adapting to ... temperatures when flying to flowers. Whether and how they ... from the University of Washington and the University of Puget ...
... Schulich School of Medicine & Dentistry at The University ... Edinburgh, have discovered a way to kill the cystic ... of Dr. Miguel Valvano, Department of Microbiology and Immunology, ... of the Journal of Bacteriology, and highlighted in Nature ...
Cached Biology News:Making mice with enhanced color vision 2Making mice with enhanced color vision 3Bumblebee house warming -- it takes a village 2Bumblebee house warming -- it takes a village 3Key found to kill cystic fibrosis superbug 2
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Request Info...
Request Info...
Biology Products: